Tonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Acquires 1,415 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Carolyn Taylor purchased 1,415 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $10.55 per share, with a total value of $14,928.25. Following the purchase, the director directly owned 1,833 shares of the company’s stock, valued at approximately $19,338.15. This represents a 338.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Tonix Pharmaceuticals Price Performance

TNXP opened at $11.35 on Monday. The stock’s fifty day moving average is $13.04 and its two-hundred day moving average is $14.93. The company has a market capitalization of $180.92 million, a P/E ratio of -0.79 and a beta of 1.67. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $10.03 and a 52 week high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The firm had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $6.13 million. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TNXP. Legal & General Group Plc bought a new stake in Tonix Pharmaceuticals during the second quarter valued at about $25,000. State of Wyoming bought a new position in Tonix Pharmaceuticals in the fourth quarter worth about $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Tonix Pharmaceuticals during the third quarter valued at about $29,000. BNP Paribas Financial Markets purchased a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at about $65,000. Finally, Leonteq Securities AG bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $89,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. Wall Street Zen lowered shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Finally, TD Cowen raised shares of Tonix Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.